Physician profile
Satheesh Joseph
NPI 1033133343
$4,563.55
in general payments reported to CMS, 2019-2025
26 companies · $734 in 2025
The $734 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,539 · 2020: $141 · 2021: $1,026 · 2022: $486 · 2023: $324 · 2024: $314 · 2025: $734.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,372.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,371.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $791.11 | 2019 | |
| Novartis Pharmaceuticals Corporation | $707.41 | 2019-2025 | |
| Abbott Laboratories | $606.05 | 2019-2022 | |
| Boston Scientific Corporation | $438.78 | 2019-2025 | Watchman Flx, Avvigo Guidance System, Varithena Administration Pack |
| Biotronik INC. | $372.09 | 2019-2024 | Biomonitor |
| Pfizer INC. | $321.15 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $308.05 | 2019-2025 | Farxiga, Lokelma |
| Astellas Pharma US INC | $197.19 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $136.03 | 2019-2025 | Eliquis, Camzyos |
| Abiomed | $129.83 | 2025 | |
| Tactile Systems Technology INC | $114.64 | 2023-2025 | Flexitouch Plus, Entre Plus, Nimbl |
| Amgen INC. | $86.80 | 2023-2025 | Repatha, Repatha |
| Regeneron Healthcare Solutions, INC. | $42.15 | 2019 | |
| Itamar Medical INC | $31.72 | 2021 | |
| Lilly USA, LLC | $30.83 | 2024 | Zepbound |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.68 | 2022 | |
| Angiodynamics, INC. | $27.56 | 2021 | |
| Alnylam Pharmaceuticals INC. | $26.97 | 2025 | Amvuttra |
| Novo Nordisk INC | $24.00 | 2024 | Wegovy |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $22.62 | 2024 | Lifevest |
| Medtronic, INC. | $21.91 | 2021 | |
| Corcept Therapeutics | $21.00 | 2025 | Korlym |
| Abbvie INC. | $20.73 | 2025 | |
| Janssen Pharmaceuticals, INC | $20.36 | 2021 | |
| Esperion Therapeutics, INC. | $19.02 | 2021 | |
| Sanofi-Aventis U.S. LLC | $16.87 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Satheesh Joseph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.